This is directed at the authors, editors, and administrators of the WHO Blue Books: 1️⃣ If a chapter relies on genetic testing unavailable to >80% of the world, it serves no one but those who already know the disease. Rewrite it. 2️⃣ If you plan to change nomenclature, ask: Does it change practice? Does it impact clinical care? If not—don’t change it. 3️⃣ If you’re adding IHC to diagnostic criteria and it’s unavailable in most countries, don’t include it—unless you’re willing to pay for it. 4️⃣ Don’t create a new entity based solely on molecular testing if it’s not actionable and/or not visible on H&E. 5️⃣ For every chapter you write, ask yourself: “Am I reducing global health inequity or increasing it?” If the answer isn’t crystal clear, start over.